All In Biotech

Drug Trial Radar · NCT04085367

Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream in the Treatment of Thin and Moderately Thick, Non-hyperkeratotic, Non-pigmented Actinic Keratosis (AK) of the Face and Scalp When Using Daylight Photodynamic Therapy (DL-PDT)

Last checked: Nov 20, 2026Latest source record: Apr 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 557 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

557

Actual

Start

Sep 30, 2019

Primary completion

Mar 3, 2021

Study completion Apr 7, 2021

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Sep 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT).

Conditions

  • Actinic Keratoses

Interventions

  • MAL 16.8% creamDrug

    Day light photodynamic therapy with MAL 16.8% cream

  • MAL Vehicle CreamDrug

    Day light photodynamic therapy with MAL vehicle cream

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete Response at Week 12Time frame: Week 12

Locations

60 sites in 2 countries. Site status is shown where the registry gives one.

  • Galderma Investigational Site (Site 8768)

    Tucson, Arizona

  • Galderma Investigational Site (Site 8447)

    Fort Smith, Arkansas

  • Galderma Investigational Site (Site 8577)

    Encinitas, California

  • Galderma Investigational Site (Site 8636)

    Fountain Valley, California

  • Galderma Investigational Site (Site 8224)

    Fremont, California

  • Galderma Investigational Site (Site 8114)

    Fresno, California

  • Galderma Investigational Site (Site 8758)

    San Diego, California

  • Galderma Investigational Site (Site 8608)

    Santa Monica, California

  • Galderma Investigational Site (Site 8778)

    Denver, Colorado

  • Galderma Investigational Site (Site 8440)

    Greenwood Village, Colorado

  • Galderma Investigational Site (Site 8479)

    Bradenton, Florida

  • Galderma Investigational Site (Site 8770)

    Lehigh Acres, Florida

  • Galderma Investigational Site (Site 8656)

    Miami, Florida

  • Galderma Investigational Site (Site 8765)

    North Miami Beach, Florida

  • Galderma Investigation Site (Site 8769)

    Palm Springs, Florida

  • Galderma Investigational Site (Site 8734)

    Pembroke Pines, Florida

  • Galderma Investigational Site (Site 8529)

    Sanford, Florida

  • Galderma Investigational Site (Site 8126)

    West Palm Beach, Florida

  • Galderma Investigational Site (Site 8683)

    Atlanta, Georgia

  • Galderma Investigational Site (Site 8860)

    Atlanta, Georgia

  • Galderma Investigational Site (Site 8667)

    Columbus, Georgia

  • Galderma Investigational Site (Site 8755)

    Boise, Idaho

  • Galderma Investigational Site (Site 8838)

    Darien, Illinois

  • Galderma Investigational Site (Site 8724)

    Louisville, Kentucky

  • Galderma Investigational Site (Site 8208)

    Beverly, Massachusetts

  • Galderma Investigational Site (Site 8574)

    Clarkston, Michigan

  • Galderma Investigation Site (Site 8757)

    Saint Joseph, Michigan

  • Galderma Investigational Site (Site 8762)

    Edina, Minnesota

  • Galderma Investigational Site (Site 8140)

    New Brighton, Minnesota

  • Galderma Investigational Site (Site 8219)

    St Louis, Missouri

  • Galderma Investigational Site (Site 8869)

    St Louis, Missouri

  • Galderma Investigational Site (Site 8048)

    Omaha, Nebraska

  • Galderma Investigational Site (Site 8420)

    Portsmouth, New Hampshire

  • Galderma Investigational Site (Site 8759)

    Albuquerque, New Mexico

  • Galderma Investigational Site (Site 8242)

    Brooklyn, New York

  • Galderma Investigational Site (Site 8733)

    New York, New York

  • Galderma Investigational Site (Site 8279)

    New York, New York

  • Galderma Investigational Site (Site 8566)

    Charlotte, North Carolina

  • Galderma Investigational Site (Site 8726)

    Wilmington, North Carolina

  • Galderma Investigational Site (Site 8595)

    Dublin, Ohio

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.